Staar Surgical reshapes board under new investor agreement

The latest update is out from Staar Surgical ( (STAA) ).

On January 14–15, 2026, STAAR Surgical entered into a cooperation agreement with major shareholder Broadwood Partners that triggered a broad reshaping of its board and leadership structure, including expanding the board from six to seven members, appointing Broadwood executives Neal C. Bradsher and Richard T. LeBuhn and Yunqi Capital’s Christopher Wang as new directors, and accepting the resignations of board chair Elizabeth Yeu, MD, and CEO Stephen C. Farrell from the board, with Farrell to remain chief executive until January 31, 2026 and then move into a one-year consulting role with severance and equity treatment consistent with his prior employment agreement. The agreement, which includes customary standstill and non-disparagement provisions and reimbursement of certain investor expenses, consolidates influence for STAAR’s largest shareholders—Broadwood, with 31% of the stock, and Yunqi, with 6.5%—while temporarily leaving the company out of compliance with Nasdaq’s audit committee independence requirements following Yeu’s departure, a deficiency STAAR has notified Nasdaq it intends to cure within the allowed period as the refreshed board moves to name a new chair and CEO and sharpen the company’s profitability and long-term value-creation strategy.

The most recent analyst rating on (STAA) stock is a Sell with a $21.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.

Spark’s Take on STAA Stock

According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.

The score is primarily held down by poor financial performance (large losses and negative cash flow) and bearish technical signals (below key moving averages with negative MACD). Valuation provides limited support due to a negative P/E and no dividend yield, and recent corporate events add uncertainty after the merger was rejected and terminated.

To see Spark’s full report on STAA stock, click here.

More about Staar Surgical

STAAR Surgical (NASDAQ: STAA) is a global leader in implantable phakic intraocular lenses (ICLs) for vision correction, offering its EVO ICL line as a minimally invasive alternative to glasses, contact lenses and corneal tissue–removal procedures. Founded in 1982 and focused exclusively on ophthalmic surgery, the company designs, develops, manufactures and markets Implantable Collamer Lenses using its proprietary biocompatible Collamer material, has sold more than 3 million ICLs in over 75 countries, and operates research, development, manufacturing and packaging facilities in California and Switzerland.

Average Trading Volume: 1,340,413

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.09B

Find detailed analytics on STAA stock on TipRanks’ Stock Analysis page.